Bosh sahifaATYR • NASDAQ
add
aTyr Pharma Inc
0,85 $
Seans yopilganidan keyin:(2,12%)+0,018
0,87 $
Yopilgan:13-mar, 19:32:13 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
0,87 $
Kunlik diapazon
0,83 $ - 0,90 $
Yillik diapazon
0,64 $ - 7,29 $
Bozor kapitalizatsiyasi
83,10 mln USD
Oʻrtacha hajm
2,33 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 3,90 mln | 8,71% |
Sof foyda | -13,96 mln | 6,71% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,14 | 22,22% |
EBITDA | -14,63 mln | 6,49% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 78,69 mln | 9,10% |
Jami aktivlari | 93,00 mln | -3,95% |
Jami passivlari | 25,72 mln | -4,75% |
Umumiy kapital | 67,29 mln | — |
Tarqatilgan aksiyalar | 98,05 mln | — |
Narxi/balansdagi bahosi | 1,26 | — |
Aktivlardan daromad | -37,05% | — |
Kapitaldan daromad | -43,08% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -13,96 mln | 6,71% |
Operatsiyalardan naqd pul | -12,20 mln | 7,13% |
Sarmoyadan naqd pul | 16,44 mln | 370,22% |
Moliyadan naqd pul | -131,00 ming | -100,70% |
Naqd pulning sof oʻzgarishi | 4,12 mln | 1 188,89% |
Boʻsh pul | -6,98 mln | 10,87% |
Haqida
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Tashkil etilgan
1-yan, 2005
Sayt
Xodimlar soni
59
